Trials / NCT05820100
Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT
Completed Observational Natural history / observational
- Sponsor
- Nanoscope Therapeutics Inc.
- Treatment
- Observational
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa, Retinal Dystrophy
- Ages
- 18 Years to no upper limit
- Enrollment
- 35 participants
- Started
- 2023-04-25
- Main results expected
- 2023-10-17
- Results posted
- Not yet
- Record last updated
- 2024-01-05
What the study is testing
This is a prospective Multi-Center Observational Study to assess the reliability and validity of the Multi-Luminance Y-Mobility Test (MLYMT) and Multi-Luminance Shape Discrimination Study (MLSDT) Main Outcome Measures: (i) Performance scores in normal and severely visually impaired subjects with a clinical diagnosis of retinitis pigmentosa (RP) on MLYMT and MLSDT at multiple luminance levels and (ii) reliability and content validity of MLYMT and MLSDT.
Where it runs
Puerto Rico (1)
- Nanoscope Clinical Site, Arecibo
United States (7)
- Nanoscope Clinical Site, Phoenix, Arizona
- Nanoscope Clinical Site, Beverly Hills, California
- Nanoscope Clinical Site, Miami, Florida
- Nanoscope Clinical Site, Fargo, North Dakota
- Nanoscope Clinical Site, Bellaire, Texas
- Nanoscope Clinical Site, McAllen, Texas
- Nanoscope Clincal Site, San Antonio, Texas